INS and Obesity: These results indicated that carvedilol treatment targeting the adrenergic overdrive in HFD-induced obesity effectively blocked the induction of gluconeogenic enzymes to suppress a hepatic glucose overproduction and enhanced the muscular insulin signaling pathway.